Core Oncology - a Management Buyout in Medical Devices
	2/20/2008 5:00PM      |  Send this page to a friend.  Cabrillo Pavilion Arts Center
	Program Description:
	Wednesday, February 20, 2008 \nCore Oncology: a Management Buyout in Medical Devices\n \nWelcome: Sejal Hall, MIT Enterprise Forum of the Central Coast\nKeynote Speaker: Trevor Pritchard, Executive Vice-President, Strawn Arnold Ashpitz Groover, Inc. (Former President of Mentor Medical)\nCase Presentation: Travis Gay, CEO, Core Oncology\nPanel Discussion: Alex J. Weinstein, M.D. and Dave Gross, Co-founder and Managing Partner, Great Pacific Capital\n\nLogistics\nWHEN:\nWednesday, February 20, 2008\nRegistration, Dinner, Cash Bar & Networking Hour: 5:00pm – 6:00pm\nSpeakers and Panel: 6:00pm – 7:30pm\nPost Presentation Cash Bar available from 7:30pm\n\nWHERE:\nCabrillo Pavilion Arts Center\n1118 E. Cabrillo Boulevard, Santa Barbara, CA 93103\n\nCOST:\n$30 pre-register online before February 20 at www.centralcoastmit.com\n$40 after February 20, or at the door\n\nPARKING:\n$2.00\n\nProgram Description\n\nWhat do you do when the new parent company of your division decides it does not fit in with the corporate strategy? This was the situation facing the management of Mentor Urology Division’s cancer radiation therapy business after Mentor sold their division to Coloplast, a Danish medical devices company.\n\nTravis Gay, the general manager of the radiation therapy business, decided to lead a management buyout (MBO) effort as he believed there was more potential for the business than did other prospective bidders. Core Oncology was formed in 2006 by Travis’ management team and it was successful in closing the buyout of the business in mid-2007.\n\nThe Core management team believed the radiation business had been an “orphan” because none of the rest of its parent’s business addressed the cancer therapy market. They believed that it could execute its current business much better as a freestanding company and pursue new opportunities in additional cancer radiation therapies.\n\nPlease join us on February 20, 2008. Trevor Pritchard, our keynote speaker, will give an overview of both technical and market trends in cancer radiation therapies. Travis, now CEO of Core Oncology, will then discuss how the MBO was accomplished and what he and his team have done since to improve execution in its traditional prostate cancer radiation (brachytherapy) business. He will also discuss their ongoing work to develop seed radiation therapies for breast and other cancers. A panel discussion will follow.\n\n\nCore Oncology\nCore Oncology was formed on September 15, 2006 for the purpose of acquiring Mills Biopharmaceuticals, a brachytherapy business owned by Coloplast who had recently acquired Mentor Corporation’s Urology Division. Due to insufficient interest from potential industry buyers, the brachytherapy management team formed Core as a vehicle for purchasing the business themselves.\n\nOn June 8, 2007, Core completed its acquisition of Mills. Originally formed in 1997 by Mentor, this business entered the radiation oncology market as the first company to offer both Iodine and Palladium brachytherapy radiation seeds. Since that time, Mills developed and successfully launched a number of innovative delivery technologies and services, and has consistently delivered strong year-on-year growth. Core’s mission is to significantly enhance the current service levels in Radiation Oncology – “raising the bar for our competitors” – while at the same time working to develop new radiation therapies for other types of cancer. Core’s management has focused the business on physician customers, working to reinforce the trust placed in them by their patients. Meeting these physicians’ core needs is Core’s primary goal and the genesis for the name – “our Customers and their Patients are our center, our focus, and our core”.\n\nThe management team is, for the most part, the same team that developed and managed the business since its inception in 1997. Management prides itself on its unique corporate culture and the high employee retention that Core has enjoyed as a result.\n\nSpeaker Biographies\n\nKeynote Speaker – Trevor Pritchard, Executive Vice-President, Strawn Arnold Ashpitz Groover, Inc.\nTrevor is a partner of Strawn Arnold Ashpitz Groover, Inc., a boutique executive search firm in business since 1974 that specializes in the biotech and medtech sectors. The firm’s client base includes a significant number of top-tier venture capital firms and their portfolio companies. \nTrevor brings to his role in executive search over 25 years of successful operating management and P&L leadership roles in the pharmaceutical and medical device industries in the United States, Europe, and Latin America. Prior to executive search, Trevor was President of Mentor Medical, the operating subsidiary responsible for global sales, marketing & business development at Mentor Corporation. Previously, he held positions of Executive Vice President of International Sales & Marketing and Executive Vice President for Business Development and Strategic Planning for Sherwood/Davis & Geck, a $1 billion medical devices company that was a Division of Wyeth. Prior to joining Wyeth, Trevor began his career at American Cyanamid where he held various general management roles in both headquarters and overseas locations. He is a Board member of Pointe Conception Medical, a development stage endoscopy company based in Santa Barbara. Trevor received his BSc. from Seton Hall University and his MBA from Columbia University.\n\nCase Presenter – Travis Gay, CEO of Core Technology\nTravis has spent the last 8 years in a management role, first at Mentor and then for Coloplast, the business that has become Core Oncology. He has 15 years of experience in the medical device industry, the last 12 of which have been focused in urology – specifically prostate cancer treatment and diagnosis. Travis' background includes three startup medical device companies which all went public, as well as two existing public companies. All five of these companies practice in the field of urology. His responsibilities have been focused in leading sales and marketing teams as well as managing product marketing and development. He has a BA from Hanover College and has done post-graduate study for a Medical Marketing degree at UCLA. Travis has been living and working Santa Barbara for the past eight years. \n\nPanelists\nAlex J. Weinstein, M.D.\nAlex J. Weinstein, M.D. graduated with honors (AOA) from the University of Pennsylvania School of Medicine in 1982. He did his residency at the Harvard Program in Urology at Brigham and Women's Hospital in Boston Massachusetts. He is certified by the American Board of Urology and is a fellow in the American College of Surgeons. He is on the Board of Directors of the Santa Barbara County Medical Society and serves on the Medical Advisory Panel and Credentials Committee at Cottage Hospital. He is a member of the American Urological Association, California Urological Association, American Association of Clinical Urologists, California Medical Society and Santa Barbara County Medical Society. He has been practicing Urology in Santa Barbara since 1987. \n\nDave Gross, Co-founder and Managing Partner, Great Pacific Capital\nCo-Founder and Managing Partner of Great Pacific Capital, Mr. Gross is also an engineer and entrepreneur. Mr. Gross has worked in the aerospace, automotive, alternative energy/transportation and Internet fields. He designed and produced early electric and hybrid electric passenger vehicles as well as hardware for various aerospace applications including the International Space Station, missions to Mars, and the longest rigid structure ever deployed in space. He was the founding CEO of Fastclick, a successful Internet advertising company acquired by ValueClick in 2005. Mr. Gross also had CFO and COO responsibilities from inception through 2003. He led Fastclick with a total of $400K in capital raised in April of 2000 through a $75M private-equity recapitalization in September of 2004. He holds degrees in Mechanical Engineering and Environmental Studies from the University of California at Santa Barbara. Mr. Gross currently serves on the boards of Celerus Diagnostics and BioIQ.
	When:
	Wednesday, February 20, 2008 5:00 PM
	Where:
	Cabrillo Pavilion Arts Center
	Cost:
	Student $15.00 Regular $30.00 At the Door $40.00 Parking $0.00